Takeda picks up 2nd FDA-approved indication for immune globulin treatment HyQvia
Fierce Pharma
JANUARY 16, 2024
It is the second indication for HyQvia, which was first endorsed in 2014. The FDA has approved Takeda's HyQvia as a maintenance therapy for CIDP.
Let's personalize your content